+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Quetiapine Fumarate Tablets Market by Indication (Bipolar Mania, Major Depressive Disorder, Schizophrenia), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Dosage Form, Strength, Product Type, Patient Age Group - Global Forecast 2025-2030- Product Image
Quetiapine Fumarate Tablets Market by Indication (Bipolar Mania, Major Depressive Disorder, Schizophrenia), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Dosage Form, Strength, Product Type, Patient Age Group - Global Forecast 2025-2030- Product Image
New

Quetiapine Fumarate Tablets Market by Indication (Bipolar Mania, Major Depressive Disorder, Schizophrenia), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Dosage Form, Strength, Product Type, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6120576
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The landscape of psychiatric therapeutics has witnessed significant transformations over the past decade, driven by evolving clinical protocols, regulatory dynamics, and patient-centric care models. As a cornerstone in the management of mood disorders and psychotic conditions, quetiapine fumarate tablets have established a critical role within treatment regimens spanning bipolar mania, major depressive disorder, and schizophrenia. With ongoing refinements in formulation science and an expanding spectrum of therapeutic indications, stakeholders across the value chain are presented with both unprecedented opportunities and complex challenges.

Against this backdrop, our executive summary offers a synthesized perspective on the key drivers defining market direction, including the interplay between clinical efficacy, safety profiles, and the shifting paradigms of healthcare delivery. Transitioning beyond traditional paradigms, the report elucidates how intellectual property landscapes, pricing pressures, and supply chain resilience are reshaping competitive dynamics. Through a structured analysis, we provide a foundation for understanding the multifaceted forces impacting the adoption, distribution, and optimization of quetiapine fumarate tablets in contemporary practice.

In-Depth Exploration of Revolutionary Formulation Advances Regulatory Evolutions and Patient-Centric Trends Reshaping Quetiapine Tablet Adoption

Over recent years, the quetiapine fumarate tablets market has undergone transformative shifts propelled by innovations in formulation technology, regulatory reinterpretations, and patient engagement strategies. Extended release formulations refined release kinetics to support once-daily dosing, improving patient adherence and reducing the burden of polypharmacy. Concurrently, immediate release variants continue to play a vital role in rapid symptom control, particularly in acute psychotic episodes.

Regulatory bodies have increasingly embraced life-cycle management strategies, approving reformulations that address tolerability and dosing flexibility, while also granting pathways for authorized generic entry under stringent bioequivalence criteria. This regulatory evolution has prompted original manufacturers to invest in novel drug delivery systems and patent strategies. At the same time, healthcare providers have adopted telemedicine and digital health platforms to monitor treatment outcomes, thereby enhancing real-world evidence generation.

As the market adapts to the integration of precision psychiatry, patient stratification based on age demographics, severity of indication, and comorbidities has become more pronounced. These developments underscore the transition from a one-size-fits-all approach to customized therapeutic regimens, with quetiapine fumarate tablets positioned as a versatile agent capable of addressing a spectrum of psychiatric presentations.

Detailed Analysis of 2025 United States Tariff Impacts on Supply Chain Realignment Pricing Structures and Patient Access Continuity

The introduction of new tariffs by the United States in 2025 has created a ripple effect across the supply chain, prompting manufacturers and distributors of quetiapine fumarate tablets to re-evaluate sourcing strategies and procurement models. With raw material costs fluctuating due to adjusted import duties, several stakeholders have pivoted toward regional suppliers to mitigate exposure to tariff-induced price volatility.

Downstream distributors have responded by renegotiating contracts and exploring consortia-based purchasing agreements to absorb incremental cost pressures. Some original formulation producers have accelerated the launch of authorized generics to sustain market access under tighter margin constraints, while independent generic manufacturers have restructured their logistics networks to optimize cross-border movements.

Despite these adjustments, the primary concern remains maintaining uninterrupted patient access. Health systems and payers have collaborated to streamline reimbursement frameworks, ensuring that cost adjustments do not compromise adherence rates or clinical outcomes. Looking ahead, continuous dialogue between regulatory authorities and industry participants will be pivotal in balancing tariff policies with public health imperatives.

Insightful Breakdown of Quetiapine Tablet Market Divisions Across Clinical Indications Distribution Channels Dosage Forms Strengths Product Types and Age Demographics

The quetiapine fumarate tablets market demonstrates considerable heterogeneity when examined through the lens of clinical indication, distribution pathways, dosage delivery, strength variants, product classification, and patient demographics. In the realm of psychiatric indications, bipolar mania holds prominence, with further delineation between bipolar I and bipolar II guiding differential prescribing patterns; similarly, schizophrenia treatment is segmented into acute crisis management and chronic maintenance phases, complemented by major depressive disorder interventions. Distribution channels reveal a bifurcation, as hospital pharmacy networks-distinguishing between non-teaching and teaching institutions-cater to inpatient and specialized care needs, whereas retail settings span both chain and independent outlets, with online pharmacies introducing digital convenience and expanded geographic reach. The dichotomy between extended release and immediate release dosage forms underscores the balance between sustained therapeutic levels and flexible titration, while strength variations-from high-dose options at 200mg and 300mg to low-dose offerings of 100mg, 50mg, and 25mg-enable tailored treatment regimens. Product type segmentation further highlights the competitive interplay between branded offerings in original and reformulated iterations and generic versions that include authorized and unbranded generics. Finally, patient age group analyses reveal targeted approaches for adults aged 18 to 44 and 45 to 64, geriatric cohorts spanning 65 to 74 and those 75 and above, and pediatric populations within 0 to 12 and 13 to 17 age brackets. This multifaceted segmentation framework provides a granular perspective on patient needs, prescribing behaviors, and supply chain optimization.

Comprehensive Regional Evaluation of Healthcare Infrastructure Payer Policies and Distribution Dynamics in Americas EMEA and Asia-Pacific for Quetiapine Tablets

Geographically, the Americas continue to be characterized by advanced healthcare infrastructure and robust reimbursement mechanisms that facilitate ready access to both branded and generic quetiapine fumarate tablets. In the United States, evolving payer policies and value-based care initiatives have increased emphasis on real-world outcomes and pharmacoeconomic validation. Meanwhile, Canada’s universal healthcare framework supports equitable distribution across provinces.

In the Europe, Middle East & Africa region, a mosaic of regulatory landscapes shapes market entry timelines and pricing strategies. Western European markets prioritize innovation adoption and premium pricing for novel formulations, whereas emerging markets in Eastern Europe, the Middle East, and Africa demonstrate selective uptake influenced by local procurement budgets and tender processes. Collaborative projects with international health organizations have also enhanced awareness and availability in underserved areas.

Across the Asia-Pacific, rapid urbanization, expanding insurance penetration, and increasing mental health awareness drive demand growth. Key markets in East Asia emphasize local manufacturing partnerships and streamlined regulatory approvals, whereas Southeast Asian and Oceanic countries leverage public-private partnerships to broaden therapeutic access. Despite diverse economic profiles, digital health platforms are gaining traction as enablers of telepsychiatry and remote medication management throughout the region.

In-Depth Competitive Landscape Analysis Detailing Strategic Alliances Product Innovations and Cost Leadership in Quetiapine Tablet Market

The competitive environment is defined by a mix of global pharmaceutical leaders and specialized generic manufacturers. Pioneering companies have reinforced their positions through incremental innovation, securing approvals for reformulated extended release versions designed to enhance safety and tolerability. Concurrently, a cadre of generics-focused organizations competes vigorously through cost leadership and accelerated production cycles, often securing volume-driven contracts with large-scale hospital systems.

Strategic alliances and licensing arrangements have become prevalent as branded product owners collaborate with local manufacturers to expand geographic reach. In contrast, independent generic producers leverage agile manufacturing platforms and streamlined regulatory filings to introduce authorized and unbranded generics rapidly after patent expirations. Quality certifications, supply chain transparency, and robust pharmacovigilance systems serve as differentiators, while targeted marketing initiatives and patient support programs further solidify brand loyalty.

Strategic Roadmap for Industry Leaders Emphasizing Formulation Innovation Digital Health Integration and Resilient Supply Chain Models

Industry leaders should prioritize the expansion of patient-centric formulation portfolios by advancing novel extended release technologies and exploring subpopulations that may benefit from specialized dosing. Investing in digital therapeutics integration and telemedicine partnerships can facilitate adherence monitoring and gather real-world evidence to support reimbursement negotiations. To mitigate tariff risks, forging regional manufacturing hubs and diversifying supplier bases will enhance resilience and cost predictability.

Engagement with key opinion leaders in psychiatry and collaborative research initiatives will help generate clinical data that differentiates product offerings. Tailored market access strategies should consider adaptive pricing models, value-based contracting, and outcomes-based agreements that align stakeholder incentives. Finally, cultivating direct-to-patient education channels and enhancing support programs will strengthen brand equity and encourage long-term adherence.

Comprehensive Multi-Method Research Framework Incorporating Clinician Insights Regulatory Data Review and Pharmacoeconomic Evaluations

This analysis synthesizes findings from a rigorous multi-method research approach combining qualitative expert interviews, primary clinician surveys, and secondary intelligence from regulatory filings, peer-reviewed journals, and industry databases. In-depth interviews with psychiatrists, pharmacists, and payers provided insights into prescribing behaviors, reimbursement challenges, and patient adherence trends. Quantitative data collection through structured questionnaires captured distribution and procurement dynamics across hospital, retail, and online pharmacy channels.

Secondary research included review of clinical trial registries, patent landscapes, and regulatory approval databases to map formulation life cycles and generic entry timelines. Product dossiers, pharmacovigilance reports, and pharmacoeconomic studies were analyzed to evaluate efficacy, safety, and cost-effectiveness. Cross-validation was performed through triangulation, ensuring that qualitative narratives aligned with quantitative trends. Geographic coverage spanned the Americas, EMEA, and Asia-Pacific, ensuring a comprehensive perspective on regional nuances and strategic implications.

Synthesis of Clinical Innovation Regulatory Trajectories and Market Dynamics Guiding the Future of Quetiapine Tablet Access and Adoption

The quetiapine fumarate tablets landscape stands at the confluence of clinical innovation, regulatory evolution, and shifting healthcare delivery models. As formulation science advances and patient-centric approaches guide prescribing behaviors, stakeholders must navigate a complex matrix of supply chain dynamics, competitive pressures, and reimbursement paradigms. A clear understanding of segmentation across indications, distribution channels, dosage forms, strengths, product types, and demographic cohorts is essential for crafting targeted strategies.

Looking forward, the integration of real-world evidence, digital adherence technologies, and value-based contracting will be pivotal in sustaining growth and ensuring patient access. Collaboration among manufacturers, healthcare providers, and payers will drive the generation of evidence that supports optimal therapeutic outcomes. By aligning strategic investments with emerging market demands and regulatory trajectories, companies can capture opportunities while mitigating risks in this rapidly evolving therapeutic segment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Bipolar Mania
      • Bipolar I
      • Bipolar II
    • Major Depressive Disorder
    • Schizophrenia
      • Acute
      • Chronic
  • Distribution Channel
    • Hospital Pharmacy
      • Non-Teaching Hospital
      • Teaching Hospital
    • Online Pharmacy
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • Dosage Form
    • Extended Release
    • Immediate Release
  • Strength
    • High Strength
      • 200mg
      • 300mg
    • Low Strength
      • 100mg
      • 25mg
      • 50mg
  • Product Type
    • Branded
      • Original Formulation
      • Reformulation
    • Generic
      • Authorized Generic
      • Unbranded Generic
  • Patient Age Group
    • Adults
      • 18 To 44
      • 45 To 64
    • Geriatrics
      • 65 To 74
      • 75 And Above
    • Pediatrics
      • 0 To 12
      • 13 To 17
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Cipla Ltd
  • Lupin Ltd
  • Aurobindo Pharma Ltd
  • Apotex Inc

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of extended-release quetiapine formulations on patient adherence in schizophrenia treatment
5.2. Price erosion in mature markets due to influx of low-cost generics post patent expiry
5.3. Regulatory fast-track approvals for quetiapine fumarate in bipolar depression across key geographies
5.4. Increasing off-label prescriptions of quetiapine for insomnia management influencing market positioning
5.5. Growing adoption of combination therapy packs containing quetiapine and mood stabilizers in Europe
5.6. Surge in telepsychiatry platforms prescribing quetiapine tablets amid remote patient monitoring trends
5.7. Manufacturing capacity expansions in India driving global supply and competitive pricing pressures
5.8. Real-world evidence studies demonstrating quetiapine safety profiles in elderly populations boosting uptake
5.9. Pipeline developments exploring subcutaneous depot formulations of quetiapine for long-term treatment
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Quetiapine Fumarate Tablets Market, by Indication
8.1. Introduction
8.2. Bipolar Mania
8.2.1. Bipolar I
8.2.2. Bipolar II
8.3. Major Depressive Disorder
8.4. Schizophrenia
8.4.1. Acute
8.4.2. Chronic
9. Quetiapine Fumarate Tablets Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Non-Teaching Hospital
9.2.2. Teaching Hospital
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
10. Quetiapine Fumarate Tablets Market, by Dosage Form
10.1. Introduction
10.2. Extended Release
10.3. Immediate Release
11. Quetiapine Fumarate Tablets Market, by Strength
11.1. Introduction
11.2. High Strength
11.2.1. 200mg
11.2.2. 300mg
11.3. Low Strength
11.3.1. 100mg
11.3.2. 25mg
11.3.3. 50mg
12. Quetiapine Fumarate Tablets Market, by Product Type
12.1. Introduction
12.2. Branded
12.2.1. Original Formulation
12.2.2. Reformulation
12.3. Generic
12.3.1. Authorized Generic
12.3.2. Unbranded Generic
13. Quetiapine Fumarate Tablets Market, by Patient Age Group
13.1. Introduction
13.2. Adults
13.2.1. 18 to 44
13.2.2. 45 to 64
13.3. Geriatrics
13.3.1. 65 to 74
13.3.2. 75 and Above
13.4. Pediatrics
13.4.1. 0 to 12
13.4.2. 13 to 17
14. Americas Quetiapine Fumarate Tablets Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Quetiapine Fumarate Tablets Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Quetiapine Fumarate Tablets Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AstraZeneca PLC
17.3.2. Teva Pharmaceutical Industries Ltd
17.3.3. Viatris Inc
17.3.4. Sandoz International GmbH
17.3.5. Sun Pharmaceutical Industries Ltd
17.3.6. Dr. Reddy's Laboratories Ltd
17.3.7. Cipla Ltd
17.3.8. Lupin Ltd
17.3.9. Aurobindo Pharma Ltd
17.3.10. Apotex Inc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. QUETIAPINE FUMARATE TABLETS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. QUETIAPINE FUMARATE TABLETS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. QUETIAPINE FUMARATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. QUETIAPINE FUMARATE TABLETS MARKET: RESEARCHAI
FIGURE 28. QUETIAPINE FUMARATE TABLETS MARKET: RESEARCHSTATISTICS
FIGURE 29. QUETIAPINE FUMARATE TABLETS MARKET: RESEARCHCONTACTS
FIGURE 30. QUETIAPINE FUMARATE TABLETS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. QUETIAPINE FUMARATE TABLETS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR I, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR I, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR II, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR II, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ACUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY NON-TEACHING HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY NON-TEACHING HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY TEACHING HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY TEACHING HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 200MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 200MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 300MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 300MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 100MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 100MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 25MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 25MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 50MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 50MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ORIGINAL FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ORIGINAL FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REFORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY REFORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY AUTHORIZED GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY AUTHORIZED GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY UNBRANDED GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY UNBRANDED GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 18 TO 44, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 18 TO 44, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 45 TO 64, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 45 TO 64, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 65 TO 74, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 75 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 75 AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 0 TO 12, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 0 TO 12, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 13 TO 17, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY 13 TO 17, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 191. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2024 (USD MILLION)
TABLE 194. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2025-2030 (USD MILLION)
TABLE 195. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2024 (USD MILLION)
TABLE 196. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2025-2030 (USD MILLION)
TABLE 197. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 200. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 201. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 206. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 207. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2018-2024 (USD MILLION)
TABLE 208. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2025-2030 (USD MILLION)
TABLE 209. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2018-2024 (USD MILLION)
TABLE 210. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2025-2030 (USD MILLION)
TABLE 211. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 214. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 215. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 216. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 217. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 218. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 219. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 220. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 221. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2018-2024 (USD MILLION)
TABLE 222. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2025-2030 (USD MILLION)
TABLE 223. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
TABLE 224. CANADA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2024 (USD MILLION)
TABLE 228. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2025-2030 (USD MILLION)
TABLE 229. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2024 (USD MILLION)
TABLE 230. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2025-2030 (USD MILLION)
TABLE 231. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 234. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 235. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 236. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 237. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 238. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 239. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 240. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 241. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2018-2024 (USD MILLION)
TABLE 242. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2025-2030 (USD MILLION)
TABLE 243. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2018-2024 (USD MILLION)
TABLE 244. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2025-2030 (USD MILLION)
TABLE 245. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 248. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 249. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 250. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 251. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 252. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 253. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 254. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 255. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2018-2024 (USD MILLION)
TABLE 256. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2025-2030 (USD MILLION)
TABLE 257. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
TABLE 258. MEXICO QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GERIATRICS, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PEDIATRICS, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BIPOLAR MANIA, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY SCHIZOPHRENIA, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY HIGH STRENGTH, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY LOW STRENGTH, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 314. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 315. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 316. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA QUETIAPINE FUMARATE TABLETS MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA QUETIAPINE FUMARATE TABLETS M

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Quetiapine Fumarate Tablets market report include:
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Ltd
  • Cipla Ltd
  • Lupin Ltd
  • Aurobindo Pharma Ltd
  • Apotex Inc

Related Topics

Related Reports

Quetiapine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Quetiapine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 85 Pages
  • Global
From
Quetiapine (CAS 111974-69-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Quetiapine (CAS 111974-69-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Antipsychotic Drugs Market by Drug Class (First Generation Antipsychotics, Second Generation Antipsychotics), Route Of Administration (Injectable, Oral), Distribution Channel, Formulation, Indication - Global Forecast 2025-2030 - Product Image

Antipsychotic Drugs Market by Drug Class (First Generation Antipsychotics, Second Generation Antipsychotics), Route Of Administration (Injectable, Oral), Distribution Channel, Formulation, Indication - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Oral Medications for Multiple Sclerosis Market by Molecule, Drug Class, Indication, Line of Therapy, Dosage Form, Distribution Channel - Global Forecast 2025-2030 - Product Image

Oral Medications for Multiple Sclerosis Market by Molecule, Drug Class, Indication, Line of Therapy, Dosage Form, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Psychotropic Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Psychotropic Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.